4 assets in Immune Dysregulation-Polyendocrinopathy-Enteropathy-X-Linked Syndrome

Therapeutic assets addressing Immune Dysregulation-Polyendocrinopathy-Enteropathy-X-Linked Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Alemtuzumab Immune Dysregulation-Polyendocrinopathy-Enteropathy-X-Linked Syndrome	Paul Szabolcs	P2	CCC (53)
Fludarabine Immune Dysregulation-Polyendocrinopathy-Enteropathy-X-Linked Syndrome	Paul Szabolcs	P2	CCC (53)
Melphalan Immune Dysregulation-Polyendocrinopathy-Enteropathy-X-Linked Syndrome	Paul Szabolcs	P2	CCC (53)
Thiotepa Immune Dysregulation-Polyendocrinopathy-Enteropathy-X-Linked Syndrome	Washington University School of Medicine	P2	CCC (53)